Pharmacological properties and biochemical mechanisms of μ-opioid receptor ligands might be due to different binding poses: MD Studies

Background:Central and peripheral analgesia without adverse effects relies on the identification of mu-opioid agonists that are able to activate 'basal' antinociceptive pathways. Recently developed mu-selective benzomorphan agonists that are not antagonized by naloxone do not activate G-proteins and beta-arrestins. Which pathways do mu receptors activate? How can each of them be selectively activated? What role is played by allosteric binding sites?Methodology & results:Molecular modeling studies characterize the amino acid residues involved in the interaction with various classes of endogenous and exogenous ligands and with agonists and antagonists.Conclusions:Critical binding differences between various classes of agonists with different pharmacological profiles have been identified. MML series binding poses may be relevant in the search for an antinociception agent without side effects.